frunevetmab

Frunevetmab is a felinized monoclonal antibody developed specifically for cats. It binds with high affinity to nerve growth factor (NGF), a protein involved in the regulation of pain, particularly in osteoarthritis. By binding NGF, frunevetmab prevents its interaction with the tropomyosin receptor kinase A (TrkA) and p75NTR receptors on peripheral nerves and other cell types, thereby inhibiting downstream signaling that leads to peripheral sensitization, neurogenic inflammation, and increased pain perception. This mechanism effectively reduces pain associated with osteoarthritis in cats. Frunevetmab is administered as a subcutaneous injection once every four weeks and is available only by prescription for veterinary use[2][3][8].

Brand names

Solensia